Document:

Exhibit 10.4

 

FIRST AMENDMENT dated as of October 16, 2014  (this “Amendment”) to the 5-Year Credit Agreement dated as of November 10, 2011 (the “Credit Agreement”), among INTERNATIONAL BUSINESS MACHINES CORPORATION (“IBM”), JPMORGAN CHASE BANK, N.A., as Administrative Agent, the Subsidiary Borrowers parties thereto (the “Subsidiary Borrowers”) , the Lenders parties thereto, and the Syndication Agents and Documentation Agents named therein. Capitalized terms used but not defined herein shall have the meanings assigned to such terms in the Credit Agreement.

 

RECITALS

 

WHEREAS, IBM has requested that the Credit Agreement be amended as set forth herein.

 

WHEREAS, pursuant to, and in compliance with the requirements of, Section 11.1 of the Credit Agreement, the Required Lenders are willing to agree to this Amendment on the terms set forth herein.

 

NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein, the parties hereto agree as follows:

 

SECTION 1.  Amendments to Credit Agreement.  As of the First Amendment Effective Date (as defined below), the Credit Agreement is hereby amended as follows:

 

(a)  By adding the following defined terms to Section 1.1 thereof in the appropriate alphabetical order:

 

“Anti-Corruption Laws”: all laws, rules and regulations of any jurisdiction applicable to the Borrower or its Subsidiaries from time to time concerning or relating to bribery or corruption.

 

“Sanctioned Country”: at any time, a country or territory that is itself the subject or target of any Sanctions (as of October 16, 2014, Cuba, Iran, North Korea, Sudan and Syria).

 

“Sanctioned Person”: at any time, (a) any Person listed in any Sanctions-related list of designated Persons maintained by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State, or by the United Nations Security Council, the European Union or any European Union member state, (b) any Person, organized or resident in a Sanctioned Country, or (c) any Person controlled (to the knowledge of the Borrower) by any such Person.

 

“Sanctions”: economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by (a) the U.S. government, including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State or (b) the United Nations Security Council, the European Union, any European Union member state or Her Majesty’s Treasury of the United Kingdom.

 

(b)  By adding the following as Section 4.14, under the heading “Anti-Corruption Laws”:

 

The Borrower has implemented and maintains in effect policies and procedures designed to ensure compliance by the Borrower, its Subsidiaries and their respective directors, officers and employees with Anti-Corruption Laws and applicable Sanctions, and the Borrower and its Subsidiaries, and to the knowledge of the Borrower, their directors, officers and employees, are in

 

[Signature Page to First Amendment]

 

 

compliance with Anti-Corruption Laws and applicable Sanctions in all material respects.  None of (a) the Borrower, any Subsidiary or any of their respective directors, officers or employees, or (b) to the knowledge of the Borrower, any agent of the Borrower or any Subsidiary that will act in any capacity in connection with or receive or direct the application of proceeds from the credit facility established hereby, is a Sanctioned Person.  No Loan or use of proceeds thereof will violate Anti-Corruption Laws or applicable Sanctions.

 

(c)  By adding the following as Section 6.4, under the heading “Anti-Corruption Laws”:

 

Maintain in effect and enforce policies and procedures designed to ensure compliance by it, its Subsidiaries and their respective directors, officers and employees, whether acting directly or through agents, with Anti-Corruption Laws and applicable Sanctions.

 

(d)  By adding the following as Section 7.5, under the heading “Anti-Corruption Laws”:

 

The Borrower and its Subsidiaries shall not use, and shall procure that the respective directors, officers and employees of the Borrower and its Subsidiaries shall not use, the proceeds of any Loan (A) in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any Person in violation of any Anti-Corruption Laws, (B) for the purpose of funding, financing or facilitating any activities, business or transaction of or with any Sanctioned Person, or in any Sanctioned Country, or (C) in any manner that would result in the violation of  any Sanctions applicable to any party hereto.

 

SECTION 2.  Conditions to Effectiveness of First Amendment.  This Amendment shall become effective on the first date (the “First Amendment Effective Date”) on which the Administrative Agent (or its counsel) shall have received duly executed counterparts hereof that, when taken together, bear the signatures of IBM, the Subsidiary Borrowers and Lenders representing the Required Lenders.

 

SECTION 3.  Effects on Credit Agreement.  Except as specifically amended herein, all provisions of the Credit Agreement shall continue to be in full force and effect and is hereby in all respects ratified and confirmed.  Except as otherwise expressly provided herein, the execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of any Lender or the Administrative Agent under the Credit Agreement or constitute a waiver of or consent to any provision of the Credit Agreement or to any further or future action on the part of IBM or the Subsidiary Borrowers that would require a waiver or consent of the Required Lenders or the Administrative Agent.

 

SECTION 4.  Expenses.  IBM shall reimburse the Administrative Agent for all reasonable and documented out-of-pocket costs and expenses, including, reasonable and documented attorneys’ fees, in connection with or relating to this Amendment.

 

SECTION 5.  Integration.  This Amendment represents the agreement of IBM, the Subsidiary Borrowers, the Administrative Agent and the Lenders with respect to the subject matter hereof, and there are no promises, undertakings, representations or warranties by the Administrative Agent or any Lender relative to subject matter hereof not expressly set forth or referred to herein.

 

SECTION 6.  GOVERNING LAW; WAIVER OF JURY TRIAL.  THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. EACH OF THE BORROWERS, THE ADMINISTRATIVE AGENT AND THE LENDERS HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES

 

 

TRIAL BY JURY IN ANY LEGAL ACTION OR PROCEEDING RELATING TO THIS AMENDMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY AND FOR ANY COUNTERCLAIM THEREIN.

 

SECTION 7.  Counterparts.  This Amendment may be executed by one or more of the parties to this Amendment on any number of separate counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument.  Delivery of an executed signature page of this Agreement by email or facsimile transmission shall be effective as delivery of a manually executed counterpart hereof.  A set of the copies of this Amendment signed by all the parties shall be lodged with IBM and the Administrative Agent.

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered by their respective proper and duly authorized officers as of the day and year first above written.

 

 

	
 
    	
INTERNATIONAL   BUSINESS MACHINES CORPORATION
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Raeleen Medrano
    
	
 
    	
 
    	
Assistant   Treasurer
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
JPMORGAN   CHASE BANK, N.A., as
    
	
 
    	
Administrative   Agent,
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Goh Siew Tan
    
	
 
    	
 
    	
Executive   Director
    

 

 

	
 
    	
Name   of Institution: JPMORGAN CHASE BANK, N.A.
    
	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Goh Siew Tan
    
	
 
    	
 
    	
 
    	
Executive   Director
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name   of Institution: Bank of America, N.A.
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Mukesh Singh
    
	
 
    	
 
    	
 
    	
Vice   President
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name   of Institution: Barclays Bank PLC
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Luke Syme
    
	
 
    	
 
    	
 
    	
Assistant   Vice President
    

 

 

	
 
    	
Name   of Institution: Banco Bilbao Vizcaya Argentaria,
    
	
 
    	
S.A. New York Branch
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Veronica Incera
    
	
 
    	
 
    	
 
    	
Managing   Director
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Mauricio Benitez
    
	
 
    	
 
    	
 
    	
Vice   President
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
Name   of Institution: BNP Paribas
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Gregory Paul
    
	
 
    	
 
    	
 
    	
Managing   Director
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Todd Rodgers
    
	
 
    	
 
    	
 
    	
Director
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
Name   of Institution: THE BANK OF NEW YORK MELLON
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Thomas J. Tarasovich, Jr.
    
	
 
    	
 
    	
 
    	
Vice   President
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
Name   of Institution: Mitsubishi UFJ Trust and Banking Corporation,
    
	
 
    	
New York Branch
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Makoto Takeda
    
	
 
    	
 
    	
 
    	
Senior   Vice President
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
Name   of Institution: Canadian Imperial Bank of Commerce, New York Branch
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Robert Robin
    
	
 
    	
 
    	
 
    	
Authorized   Signatory
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Andrew Campbell
    
	
 
    	
 
    	
 
    	
Authorized   Signatory
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
Name   of Institution: CITIBANK, N.A., as Syndication Agent
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Susan Olsen
    
	
 
    	
 
    	
 
    	
Vice   President
    

 

 

	
 
    	
Name   of Institution: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Christopher Day
    
	
 
    	
 
    	
 
    	
Authorized   Signatory
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
/s/   Remy Riester
    
	
 
    	
 
    	
 
    	
Authorized   Signatory
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
Name   of Institution: Deutsche Bank AG New York Branch
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Virginia Cosenza
    
	
 
    	
 
    	
 
    	
Vice   President
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
/s/   Ming K. Chu
    
	
 
    	
 
    	
 
    	
Vice   President
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
Name   of Institution: GOLDMAN SACHS BANK USA, as a Lender
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Rebecca Kratz
    
	
 
    	
 
    	
 
    	
Authorized   Signatory
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name   of Institution: HSBC Bank USA, N.A.
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Paul Hatton
    
	
 
    	
 
    	
 
    	
Managing   Director
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name   of Institution: Industrial and Commercial Bank of China Limited,
    
	
 
    	
New York Branch
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Mr. Yuqiang Xiao
    
	
 
    	
 
    	
 
    	
General   Manager
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name   of Institution: ING Bank NV, Dublin Branch
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Barry Fehily
    
	
 
    	
 
    	
 
    	
Country   Manager
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
/s/   Aidan Neill
    
	
 
    	
 
    	
 
    	
Director
    

 

 

	
 
    	
Name   of Institution: Intesa Sanpaolo S.p.A.
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   John J. Michalisin
    
	
 
    	
 
    	
 
    	
First   Vice President
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
/s/   Manuela Insana
    
	
 
    	
 
    	
 
    	
Vice   President
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name   of Institution: LLOYDS BANK PLC
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Stephen Giacolone
    
	
 
    	
 
    	
 
    	
Assistant   Vice President – G011
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
/s/   Joel Slomko
    
	
 
    	
 
    	
 
    	
Assistant   Vice President – S088
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name   of Institution: Mizuho Bank, Ltd.
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Bertram H. Tang
    
	
 
    	
 
    	
 
    	
Authorized   Signatory
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name   of Institution: The Northern Trust Company
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Daniel J. Boote
    
	
 
    	
 
    	
 
    	
Senior   Vice President
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name   of Institution: PNC Bank, National Association
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Michael A. Richards
    
	
 
    	
 
    	
 
    	
Senior   Vice President
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name   of Institution: Royal Bank of Canada
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Mark Gronich
    
	
 
    	
 
    	
 
    	
Authorized   Signatory
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name   of Institution: THE ROYAL BANK OF SCOTLAND PLC
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Matthew Pennachio
    
	
 
    	
 
    	
 
    	
Director
    

 

 

	
 
    	
Name   of Institution: Santander Bank, N.A.
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Marcelo Castro
    
	
 
    	
 
    	
 
    	
Managing   Director
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name   of Institution: Standard Chartered Bank
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Steven Aloupis
    
	
 
    	
 
    	
 
    	
Managing   Director
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
/s/   Hsing H. Huang
    
	
 
    	
 
    	
 
    	
Associate   Director
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name   of Institution: SOCIETE GENERALE
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Kimberly Metzger
    
	
 
    	
 
    	
 
    	
Director
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name   of Institution: State Street Bank & Trust Company
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Andrei Bourdine
    
	
 
    	
 
    	
 
    	
Vice   President
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name   of Institution: Sumitomo Mitsui Banking Corporation
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   David W. Kee
    
	
 
    	
 
    	
 
    	
Managing   Director
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name   of Institution: TORONTO DOMINION (NEW YORK) LLC
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Marie Fernandes
    
	
 
    	
 
    	
 
    	
Authorized   Signatory
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name   of Institution: UniCredit Bank AG, New York Branch
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Fabio Della Malva
    
	
 
    	
 
    	
 
    	
Director
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
/s/   Jeffrey Ferris
    
	
 
    	
 
    	
 
    	
Director
    

 

 

	
 
    	
Name   of Institution: Wells Fargo Bank, N.A.
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Eric Frandson
    
	
 
    	
 
    	
 
    	
Managing   Director
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Name   of Institution: WESTPAC BANKING CORPORATION
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Richard Yarnold
    
	
 
    	
 
    	
 
    	
Senior   Relationship Manager
    
	
 
    	
 
    	
 
    	
Corporate &   Institutional BankingEX-10.29

 Exhibit 10.29 
  

	
	  

Confidential Materials omitted and filed separately with the

Securities and Exchange Commission. Double asterisks denote omissions.

 

 EXECUTION COPY 

TERMINATION AND TRANSITION AGREEMENT 

THIS TERMINATION AND TRANSITION AGREEMENT (the
“Transition Agreement”) is made as of February 5, 2015 (the “Termination Date”), by and between DEBIOPHARM INTERNATIONAL S.A., a Swiss corporation having
its principal place of business at Forum «après-demain», Chemin Messidor 5-7, 1006 Lausanne, Switzerland (“Debiopharm”), and CURIS, INC., a corporation
established under the laws of the State of Delaware, USA, having its principal place of business at 4 Maguire Road, Lexington, MA 02421-3112, United States of America (“Curis”). 

RECITALS 

WHEREAS, Debiopharm and Curis are parties to that certain License Agreement effective as of August 5, 2009 and
dated August 6, 2009, as amended on October 26, 2009, March 30, 2011, February 6, 2012, July 16, 2012, May 20, 2013, March 26, 2014 and November 10, 2014 (collectively, the “License
Agreement”); and 
 WHEREAS, Debiopharm and Curis desire to terminate the License Agreement and to
provide for an orderly transition of rights, responsibilities and obligations relating to Compounds and Products from Debiopharm to Curis in a manner that minimizes disruption to Product development, on the terms and conditions set forth herein.

 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein
and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Debiopharm and Curis agree as follows: 
 1.
DEFINED TERMS. Capitalized terms used but not otherwise defined herein shall have the meanings provided in the License Agreement. In addition, the following terms shall have the respective meanings provided below:

 1.1 “Debio 0932 CTA” shall mean Debiopharm’s clinical trial applications (CTAs), for any and all studies
concerning the Compound, including CTAs for the studies [**], including all amendments thereto, and the “Declaration of End of Trial” for each aforementioned study. 

1.2 “EudraCT” shall mean the “European Union Drug Regulating Authorities Clinical Trials”, which is the
European database of all clinical trials of investigational medicinal products. 
 1.3 “HALO Trial” shall mean that certain
Debiopharm-sponsored clinical trial of Product described in Debiopharm Protocol No. [**].  
 1.4 “Non-Exclusive
License” shall have the meaning provided in paragraph 2.3 of this Transition Agreement. 
 1.5 “Termination
Date” shall have the meaning provided in the introductory paragraph of this Transition Agreement. 
 1.6 “Transition
Period” shall mean the period beginning on the Termination Date and expiring [**] days thereafter. 

  

					
	Termination and Transition Agreement		Debiopharm - Curis		Page 1 of 19

 EXECUTION COPY 
  

 2. TERMINATION OF LICENSE AGREEMENT.
 
 2.1 License Agreement Termination Date. The License Agreement is hereby terminated effective as of the Termination Date.
 
 2.2 Consequences of Termination. The License Agreement shall be deemed to have been terminated pursuant to
Section 12.1 of the License Agreement, and such termination shall be subject to the provisions of Section 13.1 of the License Agreement, which Section is hereby incorporated by reference in this Transition Agreement, except for
Sections 13.1(b)(i) and 13.1(b)(ii) of the License Agreement, which are superseded by the terms set forth below in this paragraph 2.2 as of the Termination Date. 

(a) Curis will make each of the following one-time payments to Debiopharm: 

(i) $750,000 (Seven Hundred and Fifty Thousand United States Dollars) within fifteen (15) days of the Termination Date, which is
in consideration of Debiopharm providing the LC14020A Material (defined in paragraph 3.7 of this Transition Agreement) to Curis as described in paragraph 3.7 of this Transition Agreement; 

(ii) $3,000,000 (Three Million United States Dollars) within thirty (30) days after the first dosing of the first patient in the
first Phase III anywhere in the Territory; and 
 (iii) $10,000,000 (Ten Million United States Dollars) within thirty
(30) days after receipt of the first marketing approval for Product in the United States of America or a Major European Market (whichever occurs first);  

(b) Curis will pay to Debiopharm royalties at the rate of three percent (3%) of Curis Net Sales (defined below) of
Products. Royalties on Curis Net Sales will be payable on a country-by-country basis from first commercial sale of a Product in a country of the Territory and ending upon the later of: (i) expiration of the last-to-expire valid claim of the
Debiopharm Patents, which valid claim covers the composition of matter, or any method of manufacture or use, of the Product (or the Compound contained therein) in such country; and (ii) the tenth (10th) anniversary of first commercial sale
of the Product in such country. For purposes of this paragraph 2.2(b), the definition of “Net Sales” set forth in Article 1 of the License Agreement shall apply mutatis mutandis to define the term “Curis Net Sales”;
 
 (c) Curis shall pay to Debiopharm ten percent (10%) of all Curis Sublicensee Royalties (defined below). For purposes
of this paragraph 2.2(c), “Curis Sublicensee Royalties” shall mean royalties paid by Third Party sublicensees to Curis or any of its Affiliates with respect to sales of Products by such Third Party sublicensees or any of their
respective further sublicensees; and 
 (d) Curis shall pay to Debiopharm: (i) fifteen percent
(15%) of all Curis Sublicensee Payments (defined below) attributable to the grant of a license or sublicense to develop or commercialize any Product other than a Psoriasis Product (defined below), provided that the maximum
aggregate amount payable by Curis to Debiopharm under this clause (i) is $20,000,000 (Twenty Million United States Dollars); and (ii) fifteen percent (15%) of all Curis Sublicensee Payments attributable to the grant of a license or
sublicense to develop or commercialize any Psoriasis Product. For purposes of this paragraph 2.2(d), “Curis Sublicensee Payments” shall mean amounts paid by Third Party sublicensees to Curis or any of 

  

					
	Termination and Transition Agreement		Debiopharm - Curis		Page 2 of 19

 EXECUTION COPY 
  

 
its Affiliates in connection with the grant of any license or sublicense with respect to Products, except that Curis Sublicensee Payments shall exclude (I) Curis Sublicensee Royalties,
and (II) any amounts paid to Curis by Third Party sublicensees to reimburse expenses incurred by Curis (e.g., FTE support, patent costs) or for purchases of Curis equity, provided that the consideration received by Curis for such
equity does not exceed the fair market value of such equity; and “Psoriasis Product” shall mean any Product in a topical formulation for local (i.e., non-systemic) delivery for the treatment
of psoriasis.  
 For the avoidance of doubt, the Parties acknowledge and agree that: (A) the license granted by Curis to
Debiopharm under Section 2.1 of the License Agreement is terminated and has reverted to Curis as of the Termination Date; (B) Section 14.1 of the License Agreement is terminated as of the Termination Date and shall be of no further
force or effect, and (C) the license regarding the Development and Use of Diagnostics Products granted by Curis to Debiopharm under the amendment dated May 20, 2013 is terminated, notwithstanding Section 10 of this amendment dated
May 20, 2013 and shall be deemed to have been terminated in accordance with Section 11 of this amendment dated May 20, 2013, and has reverted to Curis as of the Termination Date. 

2.3 Curis Exercise of Right to Obtain Non-Exclusive License. Curis hereby exercises its right
to obtain the non-exclusive license set forth in Section 13.1(b) of the License Agreement (the “Non-Exclusive License”), subject to
paragraph 2.2 of this Transition Agreement, including those provisions of Section 13.1(b) of the License Agreement that are incorporated herein by reference. The Parties agree that the Non-Exclusive
License and the Parties’ respective rights and obligations under Section 13.1(c) of the License Agreement are effective as of the Termination Date, except that, notwithstanding the provisions of clause (B) of Section 13.1(c) of
the License Agreement, Curis elects not to have Debiopharm transfer or assign the Debio 0932 CTA to Curis. 
  

	3.	TRANSITION. 

 3.1 Current Status of Development Activities.
Debiopharm hereby represents and warrants to Curis that Exhibits A and C to this Transition Agreement:  
 (a)
list all preclinical or other non-clinical studies and clinical trials of any Compound or Product conducted by or on behalf of Debiopharm, and accurately indicate, in each case, whether such study or trial
is completed or ongoing as of the Termination Date;  
 (b) describe all Product manufacturing process development,
formulation, and chemistry, manufacturing, and controls (CMC) work conducted by or on behalf of Debiopharm, and accurately indicate, in each case, whether such work is completed or ongoing as of the Termination Date; 

(c) identify each contract manufacturing organization or other vendor that has performed any Product manufacturing process development,
formulation or CMC work, or has manufactured Compound or Product, on behalf of Debiopharm; and 
 (d) describe each assay
developed by or on behalf of Debiopharm with respect to HSP90, Compound or Product, including, without limitation, any diagnostic CMC, pharmacokinetic, pharmacodynamics and clinical sample evaluation assay. 

  

					
	Termination and Transition Agreement		Debiopharm - Curis		Page 3 of 19

 EXECUTION COPY 
  

 3.2 HALO Trial. Debiopharm shall cease enrollment in all trials, including the HALO
Trial, as of the Termination Date. Subject to compliance with all applicable laws, rules and regulations, the requirements of any applicable Regulatory Authority ICH current good clinical practices, and the protocol for the HALO Trial, and
consistent with good medical judgment, applicable ethical standards and requirements, and all applicable ethics committee/institutional review board (IRB) approvals for the HALO Trial, Debiopharm shall perform each of the following obligations with
respect to the HALO Trial within the applicable period specified below:  
 (a) wind down and close out the HALO Trial at all
participating sites within [**] days after the Termination Date; 
 (b) within [**] days after completion of wind-down and
close-out of the HALO Trial in France, the United Kingdom, Spain and Hungary, complete and submit a declaration of the end of the HALO Trial (including all information required to be submitted therewith) to each of the Regulatory Authorities and
ethics committees in France, Hungary, Spain, and the United Kingdom;  
 (c) complete and deliver to Curis the final clinical
study report of the results of the HALO Trial within [**] months after the Termination Date; and 

(d) (i) supply all the required quantities of the Product to clinical sites in Spain for patients for
compassionate use only (the “Compassionate Use Patients”) for an indefinite period after the Termination Date, (ii) perform all necessary actions pertaining to this supply of
Product for such compassionate use, in accordance with the applicable laws and regulations of Spain and decisions of the relevant competent authorities, and (iii) as described in paragraph 4.2 of this Transition Agreement, provide Curis
with timely reporting of serious adverse events or other critical or reportable safety events experienced by Compassionate Use Patients, at Debiopharm’s expense and under Debiopharm’s sole responsibility.  

3.3 Transition Plan. The Parties desire: (a) to ensure an efficient and orderly transition to Curis of
ongoing Product development (other than the HALO Trial) and manufacturing process development, formulation and CMC work; and (b) to effect the efficient and expeditious transfer to Curis or its Third Party designee(s) of such Compound and
Product manufacturing technology, analytical and other assays, process development and know-how as are necessary to enable Curis or such designee(s) to manufacture Compound and Product . To that end, Debiopharm shall perform, and Curis shall
cooperate with Debiopharm in its performance of, the activities set forth in the transition plan attached to this Transition Agreement as Exhibit B (the “Transition Plan”). Debiopharm
shall perform the Transition Plan activities in accordance with all applicable laws, rules and regulations and the requirements of any applicable Regulatory Authority and shall use commercially reasonable efforts to perform each of such activities
within the time frames set forth in the Transition Plan and to complete all such activities no later than the expiry of the Transition Period. At Curis’ reasonable request from time to time during the Transition Period, Debiopharm shall make
qualified Debiopharm representatives reasonably available to Curis to provide necessary technical assistance, respond to reasonable questions and otherwise facilitate the performance of the Transition Plan. 

3.4 Data Transfer. Debiopharm shall transfer and deliver to Curis all Data and information relating to the Compound or Products in
Debiopharm’s or its Affiliates’ Control and possession (including, without limitation, final reports of all clinical trials and other studies of the Compound or any Product conducted by or on behalf of Debiopharm): (a) to the extent
that such 

  

					
	Termination and Transition Agreement		Debiopharm - Curis		Page 4 of 19

 EXECUTION COPY 
  

 
Data and information exists as of the Termination Date, promptly after the Termination Date; and (b) to the extent that such Data and information is collected or generated after the
Termination Date in the wind-down and close-out of the HALO Trial (or other clinical trials conducted by Debiopharm) or the performance of Transition Plan activities, promptly upon the collection or generation (or if generated by a Third Party,
promptly following delivery to Debiopharm) of the same. Debiopharm represents and warrants to Curis that each report of any clinical trial or other study of the Compound or any Product delivered by Debiopharm to Curis that is identified as
“final” will be in final form and will have received final internal sign-off by Debiopharm prior to delivery to Curis. 
 3.5
Raw Data and Source Documents. To the extent that Debiopharm is required by applicable law to do so, Debiopharm shall retain, or cause to be retained, all raw data and source documents underlying the Data and all regulatory submissions made by
Debiopharm or any of its Affiliates with respect to Compound or Product for the applicable retention period required by law (the “Retention Period”). Debiopharm shall, upon reasonable advance written notice by
Curis, and during regular business hours, make such raw data and source documents available at its or its contractor’s offices for review, copying and audit by Curis’ representatives. On or after the expiration of the applicable Retention
Period, Debiopharm may destroy such raw data and source documents upon [**] days’ notice to Curis, unless, during such [**]day notice period, Curis requests in writing that the originals of such raw data and source documents be delivered
to Curis or its designee, in which case Debiopharm shall deliver the same to Curis or its designee in accordance with Curis’ written direction and at Curis’ cost.  

3.6 Manufacturing Arrangements. Debiopharm shall provide contact information include primary contact name, email address and telephone
number and also shall promptly provide such introductions to contract manufacturing organizations and other vendors identified in Exhibit C hereto as Curis may request during the Transition Period, and shall deliver to each such vendor
such written notices and authorizations as may be necessary for such vendor to disclose and provide to Curis, and for Curis to access and use, the respective agreement between Debiopharm and such vendor, all data and results of the services
performed by such vendor on behalf of Debiopharm with respect to Compound or Product (“Debio 0932 Services”), including, without limitation, raw data, documentation, batch records, source documents and reports regarding
the Debio 0932 Services, and all Compound and Product material in such vendor’s possession. 
 3.7 Clinical
Material. Debiopharm represents and warrants that Exhibit D to this Transition Agreement sets forth the approximate quantity and the location of all currently available clinical material
in the possession or control of Debiopharm as of the Termination Date, including API starting material, API finished product, bulk finished product and clinical drug product, including the LC14020A Material (collectively, the “CMC
Materials”), and, except as designated as non-cGMP at Exhibit D, the CMC Materials were manufactured in accordance with cGMP. As of the Termination Date, Curis shall be the owner of all remaining Product clinical material within lot
LC14020A, which is comprised of [**] blister packages that hold a total of [**] tablets (the “LC14020A Material”), and which Curis will have the right to use in clinical studies. Within [**] days after receipt
of payment for the LC14020A Material in accordance with paragraph 2.2(a)(i) of this Transition Agreement, Debiopharm shall deliver the LC14020A Material to Curis or its designee at the address specified by Curis in writing. During the
Transition Period, Debiopharm and Curis shall determine which of the CMC Materials listed in Exhibit D shall be kept in storage, transferred to Curis or disposed of in accordance with all applicable laws and regulations. Debiopharm will retain the
agreed and selected CMC Materials to be kept in storage for a maximum period of [**] months as of the Termination Date for Curis’  

  

					
	Termination and Transition Agreement		Debiopharm - Curis		Page 5 of 19

 EXECUTION COPY 
  

 
future use; for the sake of clarity, Debiopharm will not be responsible for the retesting of such CMC Materials, including currently ongoing stability and other testing programs. Curis will
pay Debiopharm for such CMC Materials to be kept in storage at a rate that is equal to its invoiced costs (as converted to United States dollars at the Termination Date). Debiopharm will provide Curis with sufficient documentation to substantiate
invoiced cost (i.e., manufacturing contracts and related invoices). During the Transition Period, Debiopharm will provide contact information, including primary contact name, email address and telephone number for vendors listed
in Exhibit D. 
 3.8 Biological Samples. Debiopharm represents and warrants that Exhibit E to this
Transition Agreement sets forth the nature and the location of all biological samples collected by or on behalf of Debiopharm in the development of the Compound or Product that are in the possession or control of Debiopharm as of the Termination
Date. Debiopharm will provide Curis with quantities of such biological samples as requested by Curis. During the Transition Period, Debiopharm will provide contact information, including primary contact name, email address and telephone number for
vendors listed in Exhibit E. 
 3.9 Change of Sponsorship Letter. Within [**] days after the Termination Date,
Debiopharm shall submit a change of sponsorship letter to FDA transferring ownership of U.S. IND No. [**] to Curis. Curis shall submit an acknowledgment letter to the FDA, confirming its acceptance of the IND. 

 

	4.	REGULATORY.  

 4.1 Regulatory Filings. Debiopharm represents
and warrants that the CTAs listed in paragraph 1.1 of this Transition Agreement are the only INDs filed by or on behalf of Debiopharm or any of its Affiliates with respect to Compound or Product with any Regulatory Authority and ethics committee
prior to the Termination Date. Without limiting the generality of paragraph 3.2(b) of this Transition Agreement, Debiopharm shall take such actions and make such submissions to Regulatory Authorities as may be necessary to close and terminate
the Debio 0932 CTA within [**] days after the Termination Date. Notwithstanding the foregoing, Curis acknowledges that the clinical study report (“CSR”) for the HALO Trial might not be available by the expiry of the
Transition Period. Debiopharm commits to completing the CSR within [**] months after the Termination Date and deliver such CSR to Curis as soon as reasonably possible upon completion of such report.  

4.2 Safety Reporting. Until such time as the Debio 0932 CTA is closed, Debiopharm shall continue to be responsible
for Regulatory Authority and ethics committee reporting obligations under the Debio 0932 CTA. Subject to the requirements of applicable law, and actions or requests of any Regulatory Authority or ethics committee, after the CTA has been closed,
Debiopharm shall have no further Regulatory Authority or ethics committee reporting obligations or any other pharmacovigilance obligations with respect to Product; provided, however, that Debiopharm shall thereafter remain obligated to
forward promptly (and in any event within [**] days of receipt) to the Alliance Manager and the identified safety contact at Curis any adverse drug experience reports with respect to Product that Debiopharm or its Affiliates may receive from
any Third Party. Debiopharm further agrees to provide Curis with timely reporting of serious adverse events or other critical or reportable safety events experienced by Compassionate Use Patients, at Debiopharm’s expense and under
Debiopharm’s sole responsibility. 

  

					
	Termination and Transition Agreement		Debiopharm - Curis		Page 6 of 19

 EXECUTION COPY 
  

 4.3 Right of Reference and Access. Debiopharm hereby grants to Curis and its
Affiliates and Third Party licensees the right to access and cross-reference the Debio 0932 CTA and any and all filings and submissions made by Debiopharm or its Affiliates with any Regulatory Authority or ethics committee relating to Compound
or Product. Debiopharm shall, promptly upon request of Curis, file with applicable Regulatory Authorities such letters of access or cross-reference as may be necessary to accomplish the intent of this paragraph 4.3. 

 

	5.	INTELLECTUAL PROPERTY. 

 5.1 Intellectual Property
Representations and Warranties. Debiopharm represents, warrants and covenants to Curis that Debiopharm has not granted, and shall not grant, to any Third Party or Affiliate any license or right under Debiopharm Intellectual Property Rights that
would conflict with the Non-Exclusive License granted to Curis. Debiopharm further represents and warrants to Curis that, as of the Termination Date:  

(a) Debiopharm has not granted to any Third Party or Affiliate any license, sublicense or other right regarding any Compound or Product
or under Curis Intellectual Property Rights;  
 (b) the only Debiopharm Patent filed by or on
behalf of Debiopharm or any of its Affiliates on or before the Termination Date is US Patent Application No. 2014/0088138 (the “US Patent Application”);  

(c) there are no Joint Patents; 

(d) it has not received any written notice from any Third Party claiming that the manufacture, use or sale of Compound or Product by
Debiopharm prior to the Termination Date infringes any patent owned or controlled by any Third Party; and 
 (e) it is not a
party to any legal action, suit or proceeding relating to Compound, Product, Debiopharm Intellectual Property Rights or Curis Intellectual Property Rights, and it has not received any written communication from any Third Party threatening any such
action, suit or proceeding. 
 5.2 Prosecution and Maintenance of Curis Patents. Except as expressly set forth in this
paragraph 5.2, Curis shall be solely responsible for the prosecution and maintenance of Curis Patents from and after the Termination Date, at Curis’ sole expense, provided that Debiopharm shall be solely responsible for patent fees and
costs incurred prior to the Termination Date (whether invoiced to Debiopharm before or after the Termination Date). No later than [**] days after the Termination Date, Debiopharm shall notify its outside patent counsel in writing of the
transfer to Curis of full responsibility for and control over the prosecution and maintenance of Curis Patents. Debiopharm shall provide reasonable cooperation and assistance to Curis as necessary for Curis to assume full responsibility for and
control over the prosecution and maintenance of Curis Patents, such cooperation and assistance to include execution of any documents that may need to be submitted to any patent office for Curis to prosecute and maintain the Curis Patents throughout
the world. 
 5.3 Assignment to Curis of Debiopharm Patent. Effective as of the Termination Date, Debiopharm hereby assigns to
Curis all right, title and interest in and to the US Patent Application, for good and sufficient consideration as provided in this Transition Agreement, including as set forth in paragraphs 2.2(b), (c) and (d) of this Transition Agreement.
After the  

  

					
	Termination and Transition Agreement		Debiopharm - Curis		Page 7 of 19

 EXECUTION COPY 
  

 
Termination Date and promptly following Curis’ request, Debiopharm agrees to execute and deliver to Curis a patent assignment, in such form as Curis or its patent counsel reasonably deems
appropriate for filing with the U.S. Patent and Trademark Office, evidencing the assignment to Curis of the US Patent Application. The US Patent Application shall be deemed a “Curis Patent” as of the Termination Date, and
paragraph 5.2 of this Transition Agreement shall apply. 
  

	6.	MUTUAL REPRESENTATIONS AND WARRANTIES; DISCLAIMERS.  

6.1 Mutual Representations and Warranties. Each Party represents, warrants and covenants to the other that: 

(a) It is duly organized and validly existing under the laws of its state or country of incorporation, and has full corporate power and
authority to enter into this Transition Agreement and to carry out the provisions hereof;  
 (b) The execution, delivery and
performance of this Transition Agreement by it does not conflict with any agreement or instrument, oral or written, to which it is a party or by which it may be bound; and  

(c) It has not granted, and shall not grant, any right to any Third Party which would conflict with the rights granted to the other
Party hereunder.  
 6.2 Disclaimer. Except as expressly set forth in this Transition Agreement, EACH PARTY EXPRESSLY
DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THE INTELLECTUAL
PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES. 
  

	7.	INDEMNIFICATION.  

 7.1 By Debiopharm. In addition to
Debiopharm’s indemnification obligations under Section 9.1 of the License Agreement (which survive the termination of the License Agreement), Debiopharm shall indemnify, defend, and hold harmless the Curis Indemnitees from and against any
and all Losses to which any Curis Indemnitee may become subject as a result of any Claim by any Third Party to the extent such Losses arise out of or result from any breach by Debiopharm of its representations, warranties, covenants or obligations
in this Transition Agreement; except, in each case, to the extent such Claim is caused by the gross negligence or willful misconduct of Curis.  

7.2 By Curis. In addition to Curis’ indemnification obligations under Section 9.2 of the License Agreement (which survive the
termination of the License Agreement), Curis shall indemnify, defend, and hold harmless the Debiopharm Indemnitees from and against any and all Losses to which any Debiopharm Indemnitee may become subject as a result of any Claim by any Third Party
to the extent such Losses arise out of or result from (i) any breach by Curis of its representations, warranties, covenants or obligations in this Transition Agreement or (ii) the development, importation, exportation, storage, handling,
transportation, manufacture, use or other disposition of the Compound or any Product by or for Curis or its Affiliates after the Termination Date; except, in each case, to the extent such Claim is caused by the gross negligence or willful misconduct
of Debiopharm. 

  

					
	Termination and Transition Agreement		Debiopharm - Curis		Page 8 of 19

 EXECUTION COPY 
  

 7.3 Indemnification Procedures. The Parties’ respective indemnification
obligations under this Transition Agreement shall be subject to Section 9.3 of the License Agreement.  
  

	8.	CONFIDENTIALITY.  

 8.1 Confidential Information. For
clarity, Confidential Information includes information disclosed by a Party or its Affiliates to the other Party or its Affiliates after the Termination Date pursuant to this Transition Agreement; provided, however, that, from
and after the Termination Date, all Data and information regarding the Compound or the Product, regardless of which Party first disclosed such Data or information to the other Party and whether such Data or information was disclosed before or after
the Termination Date, shall be deemed the Confidential Information of Curis, and Curis shall be deemed the Disclosing Party and Debiopharm the Receiving Party with respect thereto. In addition, the Parties agree that the terms of this Transition
Agreement shall be treated as Confidential Information by both Parties. 
 8.2 Survival of Confidentiality Obligations.
Article 10 of the License Agreement shall survive termination of the License Agreement; provided, however, that, notwithstanding Article 15 of the License Agreement to the contrary, effective as of the Termination
Date:  
 (a) subject to Section 10.2 of the License Agreement and paragraph 8.3 of this Transition Agreement,
neither Party shall use the name of the other Party nor any variation or adaptation thereof, nor any trademark, tradename or other designation owned by the other Party or its Affiliates, nor the names of any of its officers, employees or agents, for
any purpose without the prior written consent of the other Party in each instance; notwithstanding the foregoing, the other Party shall in any event be entitled to be notified of and to receive a full copy of any publication or disclosure using its
name, or any variation or adaptation thereof, or any trademark, tradename or other designation that it owns; 
 (b)
Sections 10.4, 10.5 and 10.6 of the License Agreement shall terminate and be of no further force or effect; 
 (c)
Sections 10.7 and 10.8 of the License Agreement shall survive termination of the License Agreement solely with respect to Data from the HALO Trial. Except for the foregoing, neither Debiopharm nor its contractors shall have any right to
publish Data and other information regarding Compounds and Products from and after the Termination Date;  
 (d) Results of
all clinical studies performed by Debiopharm on the Compound shall be published in the EudraCT database; 
 (e) In addition to any
publication set forth in paragraph 8.2(c) of this Transition Agreement, Curis recognizes that subcontractors of Debiopharm, including without limitation academic institutions and providers of services, may ask Debiopharm to provide its consent to
public oral presentations or articles of information pertaining to their activities related to the Compound or the Product, from time to time after the Termination Date. Curis shall have the right to review and comment on any material proposed for
public oral presentation or publication by Debiopharm that includes Data or other results of preclinical or clinical development of the Compound or any Product and/or includes Confidential Information of Curis. Before any such material is submitted
for publication, Debiopharm shall deliver a complete copy to Curis at least [**] days prior to submitting the material to a publisher or initiating any other disclosure. Curis shall review any such material and give its comments to Debiopharm
within  

  

					
	Termination and Transition Agreement		Debiopharm - Curis		Page 9 of 19

 EXECUTION COPY 
  

 
[**] days of the delivery of such material to Curis. With respect to public oral presentation materials and abstracts, Curis shall make reasonable efforts to expedite review of such
materials and abstracts, and shall return such items as soon as practicable to Debiopharm with appropriate comments, if any, but in no event later than [**] days from the date of delivery to Curis. Debiopharm shall comply with Curis’
request to delete references to Curis’ Confidential Information in any such material. In addition, if any such publication contains patentable subject matter, then at Curis’ request, Debiopharm shall ensure that its subcontractor either
delete the patentable subject matter from such publication or delay any submission for publication or other public disclosure for a period of up to an additional [**] days so that appropriate patent applications may be prepared and filed. For
the sake of clarity this clause shall also apply to any public presentation or publication by Debiopharm after the Termination Date. 

8.3 Press Release. Debiopharm agrees that Curis may issue a press release upon execution of this Transition Agreement in a form
reasonably agreed to by the Parties. The Parties further acknowledge that each Party may desire or be required to issue subsequent press releases or to make other public disclosures relating to this Transition Agreement or its terms. The Parties
agree to consult with each other reasonably and in good faith with respect to the text and timing of such press releases or other public disclosures prior to the issuance thereof, provided that a Party may not unreasonably withhold consent to such
releases, and that either Party may issue such press releases as it determines are reasonably necessary to comply with laws or regulations. In addition, following the initial press release announcing this Transition Agreement, each Party shall be
free to disclose, without the other Party’s prior written consent, the existence of this Transition Agreement, the identity of the other Party and those terms of this Transition Agreement which have already been publicly disclosed in accordance
herewith. 
 8.4 Curis Right to Publish. From and after the Termination Date, Curis shall be free to publish, such as by public oral
presentation, manuscript or abstract, Data and other information regarding Compounds and Products without restriction, subject to paragraph 8.2 (a) of this Transition Agreement.  

 

	9.	MISCELLANEOUS.  

 9.1 Surviving Provisions of License
Agreement. Notwithstanding Article 15 of the License Agreement to the contrary, only Sections 8.4, 9.1, 9.2, 9.3, 9.5, 13.1 (as amended by, and subject to, paragraphs 2.2 and 2.3 of this Transition Agreement) and 13.5 and
Articles 1, 10 (as amended by, and except as set forth in, paragraph 8 of this Transition Agreement), 17, 18, 19, 20, 21 and 22 of the License Agreement shall survive termination of the License Agreement pursuant to this Transition
Agreement.  
 9.2 Incorporation by Reference. Articles 17, 19, 20, 21 and 22 of the License Agreement are hereby
incorporated by reference in this Transition Agreement, mutatis mutandis (such that all references to “this Agreement” in such Articles of the License Agreement shall be interpreted to refer to this Transition
Agreement).  
 9.3 Notices. Notices required or permitted to be made or given to either Party hereto pursuant to this
Transition Agreement or the License Agreement shall be sufficiently made or given on the date of mailing if sent to such Party by certified or registered mail, postage prepaid, addressed to it at its address set forth below or to such other address
as it shall designate by written notice to the other Party as follows: 

  

					
	Termination and Transition Agreement		Debiopharm - Curis		Page 10 of 19

 EXECUTION COPY 
  

 If to Debiopharm: 

Debiopharm International S.A. 

Forum «après-demain» 

Chemin Messidor 5-7 
 1006
Lausanne 
 Switzerland 

Attention: Director, Legal Affairs 

If to Curis: 
 Curis, Inc.

 4 Maguire Road 

Lexington, MA 02421-3112 
 USA

 Attention: Chief Executive Officer 

9.4 Complete Agreement. The Parties hereto acknowledge that this Transition Agreement and the surviving provisions of the License
Agreement set forth in paragraph 9.1 of this Transition Agreement (as expressly amended by this Transition Agreement) collectively set forth the entire agreement and understanding of the Parties, and supersede all prior written or oral
agreements or understandings with respect to the subject matter hereof and thereof (except as expressly set forth in Sections 18(a) and 18(b) of the License Agreement). 

  

					
	Termination and Transition Agreement		Debiopharm - Curis		Page 11 of 19

 EXECUTION COPY 
  

 IN WITNESS WHEREOF, the Parties have
caused this Transition Agreement to be executed by their duly authorized representatives as of the Termination Date. 
  

							
	DEBIOPHARM INTERNATIONAL S.A.		CURIS, INC.
				
	By:		 /s/ Thierry Mauvernay
		By:		 /s/ Michael P. Gray

	Name:		Thierry Mauvernay		Name:		Michael P. Gray
	Title:		Delegate of the Board		Title:		Chief Financial and Chief Business Officer
	Date:		6 February 2015		Date:		2/5/2015

 Exhibit Index: 
 EXHIBIT
A: Debiopharm Development Activities 
 EXHIBIT B: Transition Plan 

EXHIBIT C: Debiopharm Vendors for CMC Materials 
 EXHIBIT D: CMC
Materials 
 EXHIBIT E: Available Biological Samples 

  

					
	Termination and Transition Agreement		Debiopharm - Curis		Page 12 of 19

 EXECUTION COPY 
  

 EXHIBIT A 

Debiopharm Development Activities 
  

							
	 Debiopharm study number
	  	 Study title
	  	 Status
	 	 Report available

for transfer within:

	 [**]
	  	[**]	  	[**]	 	[**]

 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of 8 pages were
omitted. [**] 

  

					
	Termination and Transition Agreement	  	Debiopharm - Curis	  	Page 13 of 19

 EXECUTION COPY 
  

 EXHIBIT B 

Transition Plan 
 Debiopharm’s
responsibilities under the Technology Transfer Plan are as follows: 
 Within [**] days of the Effective Date, Debiopharm will provide Curis with the
following documentation and information in either electronic or hard copy format: 
 1. General documents: 

[**] 
 2. Other CMC
documents 
 [**] 
 3.
Study related documents: 
 [**] 

4. Transfer of Control and Responsibility from Debiopharm to Curis 

[**] 
 5. Technology Transfer
Plan Management. [**]. 

  

					
	Termination and Transition Agreement		Debiopharm - Curis		Page 14 of 19

 EXECUTION COPY 
  

 EXHIBIT C 

Debiopharm Vendors for CMC Materials 
  

			
	 Manufacturer
	  	 Responsibility

	[**]	  	[**]

 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of one page was
omitted. [**] 

  

					
	Termination and Transition Agreement	  	Debiopharm - Curis	  	Page 15 of 19

 EXECUTION COPY 
  

 EXHIBIT D 

CMC Materials 
  

									
	 Product
	  	 Storage Location
	  	 Batch number
	  	 Description
	  	 Approximate quantity

	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]
		  		  		  		  	
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]
		  		  		  		  	
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]

  

					
	Termination and Transition Agreement	  	Debiopharm - Curis	  	Page 16 of 19

 EXECUTION COPY 
  

 Deuterated compounds 

 

							
	 Product
	  	 Storage Location
	  	 Batch number
	  	 Approximate quantity

	 [**]
	  	[**]	  	[**]	  	[**]
	 [**]
	  		  	[**]	  	[**]
	                Manufacturer:	  		  		  	
	[**]	  		  		  	

 Debio 0932 Metabolites 
  

							
	 Product
	  	 Storage Location
	  	 Batch number
	  	 Approximate quantity

	 [**]
	  	[**]	  	[**]	  	[**]
	 [**]
	  		  	[**]	  	[**]
	 [**]
	  		  	[**]	  	[**]
	 [**]
	  		  	[**]	  	[**]
	 [**]
	  		  	[**]	  	[**]
	 [**]
	  		  	[**]	  	[**]
	 [**]
	  		  	[**]	  	[**]
	 [**]
	  		  	[**]	  	[**]
	 [**]
	  		  	[**]	  	[**]
	 [**]
	  		  	[**]	  	[**]
	 [**]
	  		  	[**]	  	[**]
	 [**]
	  		  	[**]	  	[**]
	[**]	  		  		  	

  

					
	Termination and Transition Agreement	  	Debiopharm - Curis	  	Page 17 of 19

 EXECUTION COPY 
  

 Debio 0932 Reference Standard 

 

							
	 Product
	  	 Storage Location
	  	 Batch number
	  	 Approximate quantity

	 [**]
	  	[**]	  	[**]	  	[**]
	 [**]
	  		  	[**]	  	[**]
	 [**]
	  		  	[**]	  	[**]
	 [**]
	  		  	[**]	  	[**]

 Others Compounds 
  

							
	 Product
	  	 Storage Location
	  	 Batch number
	  	 Approximate quantity

	 [**]
	  	[**]	  	[**]	  	[**]
	 [**]
	  		  	[**]	  	[**]
	 [**]
	  		  	[**]	  	[**]
	 [**]
	  		  	[**]	  	[**]
	 [**]
	  		  	[**]	  	[**]
	 [**]
	  		  	[**]	  	[**]
	 [**]
	  		  	[**]	  	[**]

  

					
	Termination and Transition Agreement	  	Debiopharm - Curis	  	Page 18 of 19

 EXECUTION COPY 
  

 EXHIBIT E 

Available Biological Samples 
  

									
	 Debiopharm

Study Number
	  	 Study CRO /

Central
 Labs /

Secondary

Labs
	  	 Study

title
	  	 Status
	  	 Type of samples

	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]

 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of one page was
omitted. [**] 

  

					
	Termination and Transition Agreement	  	Debiopharm - Curis	  	Page 19 of 19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}]]